LLY biotech catalysts & pipeline

ELI LILLY & CO · Data as of 2026-10-25

Upcoming catalysts

retatrutide — NDA/BLA submission

Q1 2027

The clinical data package is now complete to support global registrations for obesity, obstructive sleep apnea, and knee osteoarthritis pain, with plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027.

Source filing

sofetabart mipitecan (Sofe-M) — Conference presentation

Oct 23–Oct 27

These data will be shared in an oral presentation at the European Society for Medical Oncology (ESMO) Annual Congress in Madrid, Spain.

Source filing

Explore the free biotech catalyst calendar